Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer

PURPOSE: Docetaxel-based chemotherapy (DTX) improves overall survival (OS) of men with metastatic castration-resistant prostate cancer (mCRPC). Considering the potential existence of androgen receptors that remain active at this stage, we aimed to assess the impact of the combined use of androgen de...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, Ho Seong, Koo, Kyo Chul, Cho, Kang Su, Chung, Byung Ha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Yonsei University College of Medicine 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960371/
https://www.ncbi.nlm.nih.gov/pubmed/27401636
http://dx.doi.org/10.3349/ymj.2016.57.5.1070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960371/
https://www.ncbi.nlm.nih.gov/pubmed/27401636
http://dx.doi.org/10.3349/ymj.2016.57.5.1070

Ejemplares similares